Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations;Die Cluster-Immuntherapie bei der persistierenden allergischen Rhinitis. Sicherheitsaspekte der Anwendung eines Milben-Depotallergenpräparats

HNO

Volumn 57, Issue 11, 2009, Pages 1099-1105

  Pfaar Dr , O ^a,c   Mosges R ^b   Hormann K ^a   Klimek, L ^a,c  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allergic rhinoconjunctivitis; Cluster immunotherapy; Mite allergy; Specific hyposensitization treatment; Specific immunotherapy (SIT)

Indexed keywords

HOUSE DUST ALLERGEN;

ADOLESCENT; ADULT; ANIMAL; ARTICLE; CLUSTER ANALYSIS; DELAYED RELEASE FORMULATION; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNOLOGY; INTRACUTANEOUS TEST; MALE; METHODOLOGY; MIDDLE AGED; PERENNIAL RHINITIS;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; CLUSTER ANALYSIS; DELAYED-ACTION PREPARATIONS; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INTRADERMAL TESTS; MALE; MIDDLE AGED; RHINITIS, ALLERGIC, PERENNIAL; YOUNG ADULT;

EID: 70449523076     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-009-1946-8     Document Type: Article

References (28)

1. 2)LEN and AllerGen). Allergy 63(Suppl 86):8-160.
2. Bousquet J, Lockey RF, Malling HJ (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102(4 Pt 1):558-562. doi:10.1016/S0091-6749(98)70271-4.
3. Bousquet PJ, Demoly P, Passalacqua G et al (2007) Immunotherapy: clinical trials-optimal trial and clinical outcomes. Curr Opin Allergy Clin Immunol 7:561-566. doi:10.1097/ACI.0b013e3282f1d6a4.
4. Calderon MA, Alves B, Jacobson M et al (2007) Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev CD001936.
5. Casanovas M, Martin R, Jimenez C et al (2007) Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts. Clin Exp Allergy 37:434-440. doi:10.1111/j.1365-2222.2007.02667.x.
6. Cox L (2006) Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 97:126-137.
7. Durham SR, Walker SM, Varga EM et al (1999) Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475. doi:10.1056/NEJM199908123410702.
8. Eng PA, Borer-Reinhold M, Heijnen IA et al (2006) Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 61:198-201. doi:10.1111/j.1398-9995.2006.01011.x.
9. Hansen I, Hormann K, Stuck BA et al (2003) Cluster-Immuntherapie bei saisonaler allergischer Rhinitis: Erfahrungen zur Sicherheit einer Initialtherapie mit Depot-Allergoiden (Purethal®). Laryngorhinootologie 82:558-563. doi:10.1055/s-2003-41234.
10. Hansen I, Stuck BA, Schneider-Gene S et al (2002) Cluster-Immuntherapie bei allergischer Rhino-Konjunktivitis: Therapie und Sicherheitsaspekte. Allergologie 25:549-556.
11. Jacobsen L, Niggemann B, Dreborg S et al (2007) Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62:943-948. doi:10.1111/j.1398-9995.2007.01451.x.
12. Kleine-Tebbe J, Bergmann KC, Friedrichs F et al (2006) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergol J 15:56-74.
13. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D (2001) Neubewertung des Risikos von Test- und Therapieallergenen. Eine Analyse der UAW-Meldungen von 1991 bis 2000. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 44:709-718. doi:10.1007/s001030100201.
14. Malling H, Weeke B (1993) Position paper: Immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 48:7-35.
15. Mauro M, Russello M, Alesina R et al (2006) Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one Eur Ann Allergy. Clin Immunol 38:31-34.
16. Moreno C, Fernandez-Tavora L, Acero S et al (2003) Tolerance of a cluster schedule on the treatment of seasonal allergic respiratory disease with pollen extracts quantified in mass units. J Investig Allergol Clin Immunol 13:221-227.
17. Noon L (1911) Prophylactic inoculation of hay fever. Lancet 1:572-573.
18. Norman PS, Lichtenstein LM, Marsh DG (1981) Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol 68:460-470. doi:10.1016/0091-6749(81)90200-1.
19. Pfaar O, Klimek L, Fischer I et al (2009) Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma to inhalant allergens. Int Arch Allergy Immunol 150:102-108. doi: 10.1159/000210436.
20. Pfaar O, Hormann K, Klimek L (2006) Subcutane oder mucosale Hyposensibilisierung. MMW Fortschr Med 148:28-32.
21. Pfaar O, Klimek L (2006) Die Cluster-Immuntherapie bei allergischer Rhino-Konjunktivitis - eine Übersicht über ein neues Therapiekonzept. Hautarzt 57:875-880. doi:10.1007/s00105-006-1205-9.
22. Pfaar O, Klimek L (2008) Die spezifische Immuntherapie bei allergischer Rhinitis. HNO 56:764-775. doi:10.1007/s00106-008-1732-z.
23. Purello-D'Ambrosio F, Gangemi S, Merendino RA et al (2001) Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 31:1295-1302. doi:10.1046/j.1365-2222.2001.01027.x.
24. Riechelmann H, Bachert C, Klimek L et al (2002) Durchführung des nasalen Provokationstests bei Erkrankungen der oberen Atemwege. Allergol J 2002:29-36.
25. Subiza J, Feliu A, Subiza JL et al (2008) Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clin Exp Allergy 38:987-994. doi:10.1111/j.1365-2222.2008.02995.x.
26. Tabar AI, Echechipia S, Garcia BE et al (2005) Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 116:109-118. doi:10.1016/j.jaci.2005.05.005.
27. Tabar AI, Fernandez-Tavora L, Alonso R et al (2004) Tolerance of a cluster schedule with a house dust mite extract quantified in mass units: multicentre study. J Investig Allergol Clin Immunol 14:193-197.
28. Walker SM, Pajno GB, Lima MT et al (2001) Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 107:87-93. doi:10.1067/mai.2001.112027.